Peripheral Arterial Disease Market Report 2026

The peripheral arterial disease market size has grown strongly in recent years. It will grow from $4.74 billion in 2025 to $5.12 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to high prevalence of peripheral arterial disease, limited awareness of PAD symptoms, reliance on conventional medications, inadequate access to vascular specialists, fragmented care delivery systems.

The peripheral arterial disease market size is expected to see strong growth in the next few years. It will grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to advancements in minimally invasive endovascular procedures, growing adoption of drug-eluting devices, expansion of hospitals and specialty clinics for PAD care, rising patient awareness about early intervention, increasing use of combination therapies including lifestyle modification and drugs. Major trends in the forecast period include increasing use of ai for early diagnosis and risk assessment, rising adoption of digital and cloud-based patient monitoring systems, growing focus on genomic-based personalized pad treatments, increasing implementation of iot-enabled devices for post-treatment tracking, rising integration of smart manufacturing in pad device production.

The increasing prevalence of diabetes is expected to drive the growth of the peripheral arterial disease market in the coming years. Diabetes is a chronic metabolic condition characterized by elevated blood glucose levels. As the number of individuals living with diabetes continues to rise, the demand for treatments addressing diabetes-related complications is also increasing. Diabetes is a significant risk factor for peripheral arterial disease, as people with diabetes are more susceptible to developing atherosclerosis, which is the primary underlying cause of PAD and often requires medical intervention. For instance, in March 2024, according to reports published by the Office for Health Improvement and Disparities, a UK-based government agency, between the 15 months ending in March 2022 and those ending in March 2023, the proportion of individuals with type 1 diabetes who received eight recommended care processes increased by 22%, while among those with type 2 diabetes, the increase was 21%. Therefore, the growing prevalence of diabetes is contributing to the expansion of the peripheral arterial disease market.

Major companies operating in the peripheral arterial disease market are focusing on the development of advanced medical devices, such as intravascular lithotripsy catheters, to improve treatment effectiveness, enhance patient outcomes, and shorten recovery times for individuals with vascular conditions. An intravascular lithotripsy catheter is a medical device designed to treat calcified arterial blockages by delivering controlled shockwaves that fracture calcium deposits, thereby restoring blood flow and improving vessel compliance during procedures such as angioplasty. For example, in September 2024, Shockwave Medical Inc., a US-based medical technology company, introduced the Shockwave E8 peripheral IVL catheter. This device is designed to treat peripheral arterial disease by using targeted sonic waves to break down calcium buildup within arterial walls, helping to restore circulation while minimizing damage to surrounding tissues. Its advanced design also supports easier navigation through complex vascular structures, making it suitable for a broad patient population.

In February 2023, Abbott Laboratories, a US-based pharmaceutical company, acquired Cardiovascular Systems Inc. for $890 million. Through this acquisition, Abbott aimed to strengthen its cardiovascular product portfolio by adding complementary technologies. Cardiovascular Systems Inc. is a US-based medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular diseases.

Major companies operating in the peripheral arterial disease market are Johnson and Johnson Limited, Abbott Laboratories, Medtronic Plc, Becton Dickinson and Company, Koninklijke Philips N.V., Boston Scientific Corporation, B. Braun SE, Terumo Corp., Cook Medical LLC, Penumbra Inc., Shockwave Medical Inc., AngioDynamics Inc., Cardiovascular Systems Inc., ACIST Medical Systems Inc., SurModics Inc., QT Vascular Ltd., Avinger Inc., Mercator MedSystems Inc., VentureMed Group Ltd., Eximo Medical Ltd., LimFlow SA, Contego Medical LLC.

North America was the largest region in the peripheral artery disease market in 2025. The regions covered in the peripheral arterial disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peripheral arterial disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the peripheral arterial disease market by increasing costs of imported devices, catheters, and drugs, especially affecting hospitals and specialty clinics in North America and Europe. This has led to temporary delays in adoption, while also encouraging domestic manufacturing, promoting innovation in cost-effective PAD treatments, and improving overall supply chain resilience for medical devices and therapies.

The peripheral arterial disease market research report is one of a series of new reports that provides peripheral arterial disease market statistics, including peripheral arterial disease industry global market size, regional shares, competitors with a peripheral arterial disease market share, detailed peripheral arterial disease market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral arterial disease industry. This peripheral arterial disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peripheral arterial disease (PAD) is a medical condition marked by the narrowing or blockage of arteries that deliver blood to the extremities, most commonly the legs and feet. It is a form of atherosclerosis, in which fatty deposits, or plaque, accumulate within the arterial walls, resulting in reduced blood flow. Management of the condition typically involves a combination of lifestyle changes, medications, and medical procedures aimed at improving blood circulation to the affected limbs, relieving symptoms, and reducing the risk of complications.

The primary treatment types for peripheral arterial disease include devices, catheters, drugs, and others. Devices used for PAD encompass medical equipment designed for the diagnosis, treatment, and ongoing management of the disease. Therapeutic options are administered through various routes, including oral and parenteral methods, among others. These treatments are utilized by a range of end users, such as hospitals, specialty clinics, and others.

The peripheral artery disease market consists of sales of cardiac medical devices and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.